Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 1, 2013, Pages 1-8

  Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agent; Hepcidin; Iron metabolism

Indexed keywords

ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; CD71 ANTIGEN; ERYTHROPOIETIN; FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ANEMIA; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXIA; INFECTION; INTESTINE ABSORPTION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; KIDNEY CLEARANCE; LIVER CELL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETICULOCYTE COUNT; REVIEW;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; DOWN-REGULATION; HOMEOSTASIS; HUMANS; IRON; RENAL INSUFFICIENCY, CHRONIC; UP-REGULATION;

EID: 84873467895     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12001     Document Type: Review

References (65)

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
2. Pigeon C, Ilyin G, Courselaud B etal. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
3. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 2002;277:37597-37603.
4. Peslova G, Petrak J, Kuzelova K etal. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009;113:6225-6236.
5. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.
6. Swinkels DW, Girelli D, Laarakkers C etal. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 2008;3:e2706.
7. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004;42:387-389.
8. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients. Am J Nephrol 2005;25:586-590.
9. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 2006;81:832-837.
10. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-741.
11. Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica 2010;95:501-504.
12. Theurl I, Theurl M, Seifert M etal. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008;111:2392-2399.
13. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol 2007;82:934-945.
14. De Domenico I, Zhang TY, Koening CL etal. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010;120:2395-2405.
15. Couville P, Chaloupka R, Cellier MF. Recent progress in structure-function analyses of Nramp proron-dependent metal ion transporters. Biochem Cell Biol 2006;84:960-978.
16. Knutson MD. Iron-sensing proteins that regulate hepcidin and enteric iron absorption. Annu Rev Nutr 2010;30:149-171.
17. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011;434:365-381.
18. Vanoaica L, Darshan D, Richman L, Schümann K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab 2010;12:273-282.
19. Kuragano T, Shimonaka Y, Kida A etal. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-540.
20. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009;4:1384-1387.
21. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-693.
22. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
23. Ramos E, Kautz L, Rodriguez R etal. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 2011;53:1333-1341.
24. Corradini E, Meynard D, Wu Q etal. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 2011;54:273-284.
25. Babitt JL, Huang FW, Wrighting DM etal. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-539.
26. Finberg KE, Whittlesey RL, Fleming MD, Andrews NC. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010;115:3817-3826.
27. Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011;80:240-244.
28. Nicolas G, Chauvet C, Viatte L etal. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
29. Nemeth E, Rivera S, Gabayan V etal. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
30. Pinto JP, Ribeiro S, Pontes H etal. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008;111:5727-5733.
31. Peyssonnaux C, Zinkernagel AS, Schuepbach RA etal. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-1932.
32. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008;111:924-931.
33. Lakhal S, Schödel J, Townsend AR, Pugh CW, Ratcliffe PJ, Mole DR. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J Biol Chem 2011;286:4090-4097.
34. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009;119:1159-1166.
35. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;122:78-86.
36. Papanikolaou G, Tzilianos M, Christakis JI etal. Hepcidin in iron overload disorders. Blood 2005;105:4103-4105.
37. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-3209.
38. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007;109:353-358.
39. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-1866.
40. Ashby DR, Gale DP, Busbridge M etal. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-508.
41. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006;55:667-674.
42. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythopoietic activity. Blood 2006;108:3730-3735.
43. Malyszko J. Hepcidin assays: ironing out some details. Clin J Am Soc Nephrol 2009;4:1015-1016.
44. Kroot JJ, Kemna EH, Bansal SS etal. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009;94:1748-1752.
45. Tomosugi N, Kawabata H, Wakatabe R etal. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381-1387.
46. Zaritsky J, Young B, Wang HJ etal. Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-1056.
47. Ashby DR, Gale DP, Busbridge M etal. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-981.
48. Weiss G, Theurl I, Eder S etal. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009;39:883-890.
49. Tessitore N, Girelli D, Campostrini N etal. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996-4002.
50. van der Putten K, Jie KE, van den Broek D etal. Hepcidin-25 is a marker of the response rather than resistance to exogeneous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943-950.
51. Singh AK, Coyne DW, Shapiro W, Rizkala AR, DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferring saturation. Kidney Int 2007;71:1163-1171.
52. Coyne DW, Kapoian T, Suki W etal. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferring saturation: results of the Dialysis Patients' Response to IV iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-984.
53. Stancu S, Barsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010;5:409-416.
54. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 2010;78:769-773.
55. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease: implications for iron management. Kidney Int 2009;75:104-110.
56. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008;28:115-121.
57. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2702-2704.
58. Nicolas G, Bennoun M, Porteu A etal. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-4601.
59. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007;109:4038-4044.
60. Finberg KE, Heeney MM, Campagna DR etal. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-571.
61. Cui Y, Wu Q, Zhou Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 2009;76:1137-1141.
62. Van Buren P, Velez RL, Vaziri ND, Zhou XJ. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012;44:499-507.
63. Singh N, Agarwal AK. Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 2012;77:188-194.
64. Sasu BJ, Cooke KS, Arvedson TL etal. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115:3616-3624.
65. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010;2010:750643.